Similarly, there was also no significant difference between once-weekly insulin icodec and once-weekly insulin Fc, once-daily glargin and once-daily deglude including clinically significant hypoglycemia (Fig. 5), any adverse event (S2 Figure), serious adverse event (S3 Figure) and any injection-site reaction (S4 Figure). This evidence concerns the gene INS and Hypoglycemia.